Laura Konstantaki

Cambridge, UK, Boston MA, USA and Villigen, Switzerland, 17 February 2026. Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership. The collaboration brings together eProtein Discovery’s™ rapid multiplex membrane protein screening with leadXpro’s AI/ML-driven construct design and membrane […]

Read More

Eschborn, Germany and Villigen, Switzerland — 27/01/2026 — Partex.AI (“Partex”), an AI-driven therapeutic asset incubator and accelerator, and leadXpro AG (“leadXpro”), a Switzerland-based pharmaceutical research and development company, today announced that they have entered into a collaboration agreement focused on expanding the therapeutic potential and supporting the future out-licensing of leadXpro’s adenosine A2B receptor (A2BR) […]

Read More

Membrane proteins serve as a cell’s vital link to its external environment and play crucial roles in both health and disease. Although they make up only about a quarter of the human proteome, they are the targets of more than half of all approved drugs. However, studying these proteins in the lab is challenging due […]

Read More